Thermo Fisher Scientific is investing more than $50 million in its global bioproduction capabilities to provide additional capacity for manufacturing single-use bioprocess container (BPC) systems.
 
Thermo Fisher’s single-use technologies are used for critical, sterile liquid-handling applications in the biopharmaceutical industry to help increase productivity and ensure quality in the production of biologic drugs.
 
“The demand for our bioproduction products and services continues to outpace the market,” said Cory Stevenson, president, bioproduction business, Thermo Fisher. “These investments will expand capabilities across our existing bioproduction network while we look to extend our footprint into new regions to meet increasing customer demand for our industry-leading single-use technologies.”
 
In Cramlington, UK, Thermo Fisher will expand assembly capacity and add BPC systems manufacturing. The proximity of these capabilities to customers in Europe will shorten lead times and improve overall global efficiency.
 
In the U.S., the company will expand cleanroom space for BPC chamber and related assembly production processes at its site in Logan, Utah, and further expand capacity at its site in Millersburg, Penn.
 
Construction is expected to be completed by the end of 2020.